Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
GOSS
GOSS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GOSS News
Investment Opportunities in Oversold Healthcare Stocks
3d ago
Yahoo Finance
Investment Opportunities in Oversold Healthcare Stocks
5d ago
Benzinga
Gossamer Bio's Phase 3 Trial Misses Key Endpoint
6d ago
PRnewswire
Gossamer Bio Under Investigation After 80.1% Stock Plunge Following Trial Failure
Mar 01 2026
Businesswire
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Gossamer Bio Under Investigation After 80% Stock Plunge
Feb 26 2026
PRnewswire
Gossamer Bio Reports Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension
Feb 24 2026
Benzinga
Wall Street Analysts Adjust Ratings
Feb 24 2026
Benzinga
U.S. Stocks Decline as Dow Jones Drops Over 700 Points
Feb 23 2026
Benzinga
Gossamer Bio Under Investigation After 75% Stock Plunge
Feb 23 2026
Newsfilter
Gossamer Bio Under Investigation After 75% Stock Plunge
Feb 23 2026
Globenewswire
Gossamer Bio's Seralutinib Trial Results Mixed Amid Regulatory Strategy Review
Feb 23 2026
stocktwits
Gossamer Bio Under Investigation After 70% Stock Plunge Following Trial Results
Feb 23 2026
Globenewswire
Gossamer Bio's Phase 3 Trial Results Disappoint
Feb 23 2026
Benzinga
U.S. Stocks Mixed in Morning Trade; Energy Shares Rise
Feb 23 2026
Benzinga
GOSSAMER BIO STOCK DROPS 78% FOLLOWING FAILURE OF LUNG CONDITION DRUG IN LATE-STAGE TRIAL
Feb 23 2026
moomoo
Show More News
